Codexis Enters into $60 Million Term Loan Facility with Trinity Capital
Key Highlights
- ➤$60 million senior secured term loan facility signed with Trinity Capital
- ➤$42.5 million total debt outstanding after retiring Innovatus-held debt
- ➤48 months of interest-only payments precede 12-month amortization beginning November 2030
- ➤Proceeds support siRNA therapeutics growth initiatives and ECO Synthesis platform industrialization
Expert Statements
Georgia Erbez, Chief Financial Officer and Chief Business Officer of Codexis
“We are pleased to enter into this partnership with Trinity Capital, as this refinancing enhances our financial position as we look ahead to executing on our upcoming key milestones.”
Georgia Erbez, Chief Financial Officer and Chief Business Officer of Codexis
“The new facility provides us with flexibility in our capital structure to advance many of our growth initiatives in the siRNA therapeutic sector.”
Georgia Erbez, Chief Financial Officer and Chief Business Officer of Codexis
“Industrializing our ECO Synthesis platform is a primary objective, and achieving important milestones in both GMP manufacturing and scale-up of oligonucleotide synthesis underpins the expansion of our position and influence in the industry.”
Rob Lake, Senior Managing Director, Healthcare & Life Sciences at Trinity Capital
“Providing growth capital to innovative companies operating in attractive, high-growth markets is a core focus of Trinity Capital’s business strategy.”
Rob Lake, Senior Managing Director, Healthcare & Life Sciences at Trinity Capital
“We are excited to work with Codexis in support of their vision to prove and industrialize the siRNA manufacturing process with their ECO Synthesis(®) Manufacturing Platform and are pleased to facilitate Codexis’s continued development.”
REDWOOD CITY, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into a $60 million senior secured term loan agreement with Trinity Capital Inc. (NYSE: TRIN), a leading provider of flexible capital solutions for life sciences and healthcare industries. The Company used the proceeds of the first tranche of this transaction to retire the debt that was held by Innovatus Life Sciences Lending Fund I, LP, which would have begun amortizing in March 2027. Post-closing, the Company has a total of $42.5 million in outstanding debt. The Trinity term loan provides for 48 months of interest-only payments followed by a 12-month amortization period beginning November 2030.
“We are pleased to enter into this partnership with Trinity Capital, as this refinancing enhances our financial position as we look ahead to executing on our upcoming key milestones,” said Georgia Erbez, Chief Financial Officer and Chief Business Officer of Codexis. “The new facility provides us with flexibility in our capital structure to advance many of our growth initiatives in the siRNA therapeutic sector. Industrializing our ECO Synthesis platform is a primary objective, and achieving important milestones in both GMP manufacturing and scale-up of oligonucleotide synthesis underpins the expansion of our position and influence in the industry.”
Get started
Create a free account to read the full story.